NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa

Parkinson Disease Clinical Trial

Official title:

A Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetics Study in Parkinson's Disease (PD) Participants Treated With Carbidopa/Levodopa and NE3107

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05083260
• Other study ID #: NM201
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: January 4, 2022
• Est. completion date: January 4, 2023

Study information

• Verified date: February 2023
• Source: BioVie Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A 28-day phase 2a, double-blind, placebo-controlled (1:1), multi-center study of 20 mg NE3107, twice daily of safety, potential drug-drug interactions, and MDS-UPDRS defined activity in patients with Parkinson's disease . Study will enroll 40 patients that are currently taking immediate release levodopa/ carbidopa (IRLC) and have a practically defined early morning off-state for IRLC. Day one- baseline UPDRS and IRLC PK sampling; day 2- start NE3107 dosing, assess UPDRS during onset and NE3107 PK sampling, rescue meds as needed after 4 hours; day 3 and 14- NE3107 + IRLC UPDRS assessment and PK sampling; day 28- NE3107 + IRLC UPDRS assessments. Optional overnight stays in clinic prior to Day 1-3, 14, and 28.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 46
• Est. completion date: January 4, 2023
• Est. primary completion date: November 21, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 30 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Men or women at least 30 and no more 80 years of age

2. Diagnosis of PD consistent with UK Brain Bank Criteria or MDS Research Criteria for the Diagnosis of PD, with bradykinesia and a clear motor response to levodopa

3. Stable doses of all PD medications for at least 4 weeks prior to Screening

4. Carbidopa/levodopa dose of at least 300 mg daily, distributed over a minimum of 3 dosing intervals during waking hours

5. Participants must have history of motor fluctuations with reliable early-morning OFF episodes and a history of a good response to levodopa, in the judgement of the investigator

6. If of reproductive potential, willing and able to use a highly effective form of birth control during the study and for 30 days following last dose of study drug. Examples of highly effective forms of birth control are:

1. Surgical sterility (via vasectomy, hysterectomy, or bilateral tubal ligation) or postmenopausal status in females

2. Sexual partner who is sterile or of the same sex

3. Double-barrier method (any combination of physical and chemical methods)

4. Intrauterine device in females not containing hormones.

7. Able and willing to comply with study drug administration, scheduled visits, treatment plan, laboratory tests, and other study-related procedures to complete the study

8. Investigational Review Board/Ethics Committee-approved consent form signed and date by the participant

9. Assessed as an appropriate and suitable candidate by the Enrollment Authorization Committee (EAC)

Exclusion Criteria:

1. Diagnosis of secondary or atypical parkinsonism

2. Severe or disabling fluctuations or dyskinesias that would, in the opinion of the investigator, interfere with completion of the study

3. Clinically significant cognitive impairment

4. Clinically significant hallucinations or delusions

5. Clinically significant orthostatic hypotension

6. Currently active major depression as determined by BDI-II score of >19

7. Previous surgical procedure for PD (Duopa, DBS, etc.)

8. History of small bowel or gastric surgery

9. History of clinically significant GI abnormality (inflammatory bowel disease, significant motility disorder or emesis of any cause, etc.)

10. Use of long-acting levodopa formulations (Sinemet CR, ER, Rytary, etc.)

11. Routine use of proton pump inhibitors or H2 blockers

12. Routine use of medications that may influence gastric motility (opiates, TCA antidepressants, anticholinergics, etc.)

13. Other clinically significant medical, surgical, psychiatric, or laboratory abnormality that, in the judgment of the investigator, is likely to interfere with study compliance or assessment of safety or efficacy

14. 14) Evidence of significant hepatic impairment according to Child-Pugh criteria, history of cirrhosis, and/or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels greater than 2.5 times the upper limit of normal (ULN), evidence of ascites, hepatic encephalopathy, bilirubin greater than 2 mg/dL, albumin less than 2.0 g/dL, and INR of 1.5 and greater

15. Significant renal impairment as determined by creatinine clearance (CrCL) less than or equal to 50 mL/min

16. Participant has an ECG or clinical evidence of potentially unstable heart disease, including the following:

1. QTcF > 470 msec females; > 450 msec males

2. Complete right or left bundle branch block

3. Ischemia or myocardial infarct within 1 year prior to the Screening Visit

4. Clinically significant atrial or ventricular dysrhythmia; the heart must be in predominantly normal sinus rhythm

5. Second- or third-degree AV block

6. Heart failure of NYHA classification III or greater

7. Serious cardiomyopathy or cardiac structural abnormality

8. Symptomatic coronary artery or ischemic cardiac disease

9. Any other cardiac condition that the Investigator feels may predispose the participant to ischemia or arrhythmia.

17. Current (or within past 12 months) diagnosis or history of substance abuse, including alcohol (excluding nicotine or caffeine) by Diagnostic and Statistical Manual of Mental Disorders 5 criteria, or positive urine drug screen for tetrahydrocannabinol or any drugs that may affect participant safety or interfere with efficacy assessments

18. Medical or recreational use of marijuana or CBD within 3 months of the Screening Visit

19. Active suicidal ideation within 1 year prior to Screening Visit as determined by a positive response to Question 4 or 5 on the C-SSRS

20. Currently lactating or pregnant, or planning to become pregnant during the study

21. Current participation in another investigational clinical study and/or receipt of any investigational drug within 90 days prior to screening

22. Prior randomization into this study

23. Diabetes requiring insulin treatment

24. Use of potent CYP3A4 inhibitors clarithromycin, erythromycin, diltiazem, itraconazole, ketoconazole, ritonavir, and verapamil, and potent CYP2C9 and CYP2C19 inhibitors, amiodarone, fluconazole, miconazole, piperine, fluoxetine, fluvoxamine, and ticlopidine.

25. History of breast cancer

26. History of Covid-19 (SARS-CoV-2) infection within 6-weeks prior to screening. Subjects with unresolved symptoms of Covid-19 infection or ongoing cognitive or other deficits attributable to post-Covid-19, that may affect participant safety or interfere with efficacy assessments, based on the Investigator's clinical judgment.

Related Conditions & MeSH terms

• Parkinson Disease

Intervention

Drug:
• NE3107
NE3107 is an investigational orally bioavailable, blood-brain barrier permeable anti-inflammatory agent with a new mechanism of action targeting multiple mechanisms of pathology in Parkinson's disease
• placebo
Hard gelatin capsule containing only common excipients for oral formulations

Locations

Country	Name	City	State
United States	Parkinson's Disease & Movement Disorders Center Of Boca Raton	Boca Raton	Florida
United States	Duke University	Durham	North Carolina
United States	Rocky Mountain Movement Disorders Center	Englewood	Colorado
United States	Quest Research Institute	Farmington Hills	Michigan
United States	Velocity	Hallandale Beach	Florida
United States	Charter Research	Lady Lake	Florida
United States	EZY Medical Research	Miami	Florida
United States	First Excellent Research	Miami	Florida
United States	First Excellent Research Group	Miami	Florida
United States	Premier Clinical Research Institute	Miami	Florida
United States	New York Neurology Associates	New York	New York
United States	M3 Wake Research	Raleigh	North Carolina
United States	Texas Institute for Neurological Disorders	Sherman	Texas
United States	Inland Northwest Research	Spokane	Washington
United States	University of Toledo	Toledo	Ohio
United States	Charter Research	Winter Park	Florida

Sponsors (1)

Lead Sponsor	Collaborator
BioVie Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline (day 1) in Motor disease society- Unified Parkinson's disease rating scale Part III total score for the patient in the "off-state" (without L-dopa for previous eight hours)	Unified Parkinson's disease rating scale Part III total score is the cumulative score of a 33 question assessment of disease impact on patient's ability to move, with each part scored on a scale of 0-4, with 0 being no effect of disease and 4 being severe disease. a total score of 0 indicates no disease and a total score of 132 indicates the most severe disease	measured on day 1, 2, 3, 14, and 28
Primary	Change from baseline in the length of time during which L-dopa therapy is ineffective in reducing motor symptoms of disease (OFF time)	The total sum of time in which a patient self categorizes themselves as in the "off" state determined by diary entries. 0 hours is the minimum/best score, which indicates continuous L-dopa-like activity for the 24 hour period. 24 hours is the worst score and indicates that there was no L-dopa-like benefit at any time during the 24 hour period.	off time will be measured/recorded every day from day 2 to day 27
Primary	Change from baseline in average Motor disease society- Unified Parkinson's disease rating scale Part III total score measured over the course of 8 hours after taking L-dopa and/or NE3107	An average score will be calculated from assessments of the Unified Parkinson's disease rating scale Part III total score, which is the cumulative score of a 33 question assessment of disease impact on patient's ability to move, with each question scored on a scale of 0-4, with 0 being no effect of disease and 4 being severe disease. a total score of 0 indicates no disease and a total score of 132 indicates the most severe disease. Scores will be collected several times during the eight hours following L-dopa and/or NE3107 administration.	measured on day 1, 2, 3, 14, and 28
Primary	Motor disease society- Unified Parkinson's disease rating scale Part I total score	the cumulative score of a 13 question assessment of disease impact on patient's cognitive impairment, with each question scored on a scale of 0-4, with 0 being no effect of disease and 4 being severe disease. a total score of 0 indicates no disease and a total score of 42 indicates the most severe disease. This test asks about the impact of disease on cognition, but does not directly measure cognitive capability.	measured on day 1, 2, 3, 14, and 28
Primary	Motor disease society- Unified Parkinson's disease rating scale Part 2 total score	the cumulative score of a 13 question assessment of disease impact on patient's Motor Aspects of Experiences of Daily Living, with each question scored on a scale of 0-4, with 0 being no effect of disease and 4 being a severe effect. a total score of 0 indicates no disease and a total score of 42 indicates the most severe disease.	measured on day 1, 2, 3, 14, and 28
Primary	Change from baseline in the length of time during which L-dopa-like effects are felt by the patient	The total sum of time in which a patient self categorizes themselves as in the "on" state, with or without dyskinesia determined by diary entries. 0 hours is the minimum/worst score, which indicates no L-dopa-like activity for the 24 hour period. 24 hours is the best score and indicates that there was no L-dopa-like benefit at any time during the 24 hour period.	baseline and day 1, 2, 3, 14, and 28
Primary	change from baseline in L-dopa induced dyskinesia measured with the abnormal involuntary movement scale (AIMS)	AIMS is a 12-item clinician-rated scale to assess severity of dyskinesias (orofacial movements and extremity and truncal movements) in patients taking L-dopa. Questions assess the overall severity, incapacitation, and the patient's level of awareness of the movements, and distress associated with them. Questions are scored from 0 (no symptom) to 4 (severe). the minimum total score of 0 indicates no dyskinesia and the maximum total score of 48 indicates severe dyskinesia.	AIMS will be measured during the 8 hour period of observation on Day 1, 2, 3, 14, and 28
Primary	change from baseline in time to onset of L-dopa-like activity	Length of time from L-dopa administration to beginning of L-dopa activity producing "on-state". Patient self assessment of the time L-dopa-like activity begins after L-dopa administration. A decrease in the time to onset may shorten the time in the off-state and be considered a patient benefit. An increase in time to onset may lengthen time in the off-state and be considered a general worsening of response to treatment.	measured on Day 1, 2, 3, 14, and 28
Primary	Change from baseline in Non-Motor Symptom Assessment Scale for Parkinson Disease (NMSS)	The Non-Motor Symptoms Scale (NMSS) is a 30-item rater-based scale to assess a wide range of non-motor symptoms in patients with Parkinson's disease (PD). The NMSS measures the severity and frequency of non-motor symptoms across nine dimensions. The scale can be used for patients at all stages of PD. For each question, scores of severity (0 to 3, with 0 being none and 3 being major source of distress) and frequency (1 to 4, 1= rarely and 4 = very frequent) are recorded and the product of the two calculated. The sum of the products yields the overall score. The minimum total score of 0 indicates no non-motor symptoms and the maximum score of 360 indicates severe disease.	Measured on Day 1, 2, 3, 14, and 28
Primary	change in area under the levodopa plasma concentration vs. time curve when administered alone compared to being co-administered with NE3107	the plasma concentration vs time curve for L-dopa will be calculated from the L-dopa concentration in plasma samples collected prior to dosing and at 0.5, 1, 2, 3, 4, and 8 hours after L-dopa administration on days on which NE3107 is not administered (Day 1) and three days on which NE3107 is co-administered (Day 2, 3, and 14). Changes in L-dopa area under the curve could be associated with changes in activity against motor symptoms of disease.	Blood samples will be collected on Day 1, 2, 3, and 14
Primary	Change in the maximum plasma concentration (Cmax) of levodopa when administered alone compared to being co-administered with NE3107.	the maximum plasma concentration for L-dopa will be determined in plasma samples collected prior to dosing and at 0.5, 1, 2, 3, 4, and 8 hours after L-dopa administration on days on which NE3107 is not administered (Day 1) and three days on which NE3107 is co-administered (Day 2, 3, and 14). Changes in L-dopa Cmax could be associated with changes in activity against motor symptoms of disease.	Blood samples will be collected on Day 1, 2, 3, and 14
Primary	The area under the NE3107 plasma concentration vs. time curve when administered alone compared to being co-administered with	the plasma concentration vs time curve for NE3107 will be calculated from the NE3107 concentration in plasma samples collected prior to dosing and at 0.5, 1, 2, 3, 4, and 8 hours	Blood samples will be collected on Day 2, 3, and 14
Primary	Change in the maximum plasma concentration (Cmax) of NE3107 when administered alone compared to being co-administered with L-dopa	the maximum plasma concentration for NE3107 will be determined in plasma samples collected prior to dosing and at 0.5, 1, 2, 3, 4, and 8 hours after NE3107 administration	Blood samples will be collected on Day 2, 3, and 14